Phase II studies utilizing M7824, including a study combining M7824 and a therapeutic cancer vaccine targeting prostate specific antigen (PSA) or carcinoembryonic antigen (CEA) plus mucin 1 (MUC1), are currently planned or ongoing in multiple tumor types. The gene discussed is CEACAM5; the disease is neoplasm.